Fig. 5: Longitudinal assessment of mutation abundance in plasma cfDNA upon R-CHOP treatment according to interim PET scan. | Blood Cancer Journal

Fig. 5: Longitudinal assessment of mutation abundance in plasma cfDNA upon R-CHOP treatment according to interim PET scan.

From: Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort

Fig. 5

a Distribution of the cfDNA mean VAFs of the patients at the different times of follow-up (diagnosis, mid-treatment, end of treatment, and 6 months post-treatment). b Evolution of the cfDNA mean VAFs for each patient throughout treatment. c ΔVAF values in plasma according to the ΔSUVmax (left) or Deauville score (right) between diagnosis and mid-treatment. The vertical dashed lines represent the cut-off ΔSUVmax of 70% (left) or Deauville score of 3 (right), and the blue dots represent patients with ΔVAF <90%

Back to article page